THESEUS PHARMACEUTICALS INC (THRX) Fundamental Analysis & Valuation

NASDAQ:THRX • US88369M1018

Current stock price

4.06 USD
0 (0%)
At close:
4.08 USD
+0.02 (+0.49%)
After Hours:

This THRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. THRX Profitability Analysis

1.1 Basic Checks

  • In the past year THRX has reported negative net income.
  • THRX had a negative operating cash flow in the past year.
THRX Yearly Net Income VS EBIT VS OCF VS FCFTHRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

  • THRX has a better Return On Assets (-24.13%) than 60.70% of its industry peers.
  • THRX has a Return On Equity of -25.22%. This is in the better half of the industry: THRX outperforms 70.65% of its industry peers.
Industry RankSector Rank
ROA -24.13%
ROE -25.22%
ROIC N/A
ROA(3y)-57.73%
ROA(5y)N/A
ROE(3y)-68.96%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THRX Yearly ROA, ROE, ROICTHRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 200 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for THRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
THRX Yearly Profit, Operating, Gross MarginsTHRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. THRX Health Analysis

2.1 Basic Checks

  • THRX has about the same amout of shares outstanding than it did 1 year ago.
  • THRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
THRX Yearly Shares OutstandingTHRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M
THRX Yearly Total Debt VS Total AssetsTHRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

  • THRX has an Altman-Z score of 9.94. This indicates that THRX is financially healthy and has little risk of bankruptcy at the moment.
  • THRX has a better Altman-Z score (9.94) than 85.57% of its industry peers.
  • THRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.94
ROIC/WACCN/A
WACCN/A
THRX Yearly LT Debt VS Equity VS FCFTHRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M 100M 150M 200M

2.3 Liquidity

  • THRX has a Current Ratio of 29.94. This indicates that THRX is financially healthy and has no problem in meeting its short term obligations.
  • THRX's Current ratio of 29.94 is amongst the best of the industry. THRX outperforms 97.51% of its industry peers.
  • A Quick Ratio of 29.94 indicates that THRX has no problem at all paying its short term obligations.
  • THRX's Quick ratio of 29.94 is amongst the best of the industry. THRX outperforms 98.01% of its industry peers.
Industry RankSector Rank
Current Ratio 29.94
Quick Ratio 29.94
THRX Yearly Current Assets VS Current LiabilitesTHRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. THRX Growth Analysis

3.1 Past

  • The earnings per share for THRX have decreased strongly by -12.61% in the last year.
EPS 1Y (TTM)-12.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 16.83% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-0.43%
EPS Next 2Y12.36%
EPS Next 3Y13%
EPS Next 5Y16.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
THRX Yearly Revenue VS EstimatesTHRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 100M 200M 300M 400M
THRX Yearly EPS VS EstimatesTHRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

0

4. THRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for THRX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for THRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
THRX Price Earnings VS Forward Price EarningsTHRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
THRX Per share dataTHRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as THRX's earnings are expected to grow with 13.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.36%
EPS Next 3Y13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. THRX Dividend Analysis

5.1 Amount

  • THRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

THRX Fundamentals: All Metrics, Ratios and Statistics

THESEUS PHARMACEUTICALS INC

NASDAQ:THRX (2/13/2024, 8:11:21 PM)

After market: 4.08 +0.02 (+0.49%)

4.06

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-17
Earnings (Next)03-07
Inst Owners0.03%
Inst Owner Change0%
Ins Owners13.19%
Ins Owner Change0%
Market Cap181.28M
Revenue(TTM)N/A
Net Income(TTM)-56.62M
Analysts77.78
Price Target5.36 (32.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.53%
Min EPS beat(2)7.48%
Max EPS beat(2)15.58%
EPS beat(4)4
Avg EPS beat(4)16.53%
Min EPS beat(4)7.48%
Max EPS beat(4)22.6%
EPS beat(8)6
Avg EPS beat(8)6.59%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.44%
EPS NY rev (1m)0%
EPS NY rev (3m)10.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.81
EV/EBITDA N/A
EPS(TTM)-1.34
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0
BVpS5.03
TBVpS5.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -24.13%
ROE -25.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.73%
ROA(5y)N/A
ROE(3y)-68.96%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 29.94
Quick Ratio 29.94
Altman-Z 9.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.42%
EPS Next Y-0.43%
EPS Next 2Y12.36%
EPS Next 3Y13%
EPS Next 5Y16.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-168.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-168.03%
OCF growth 3YN/A
OCF growth 5YN/A

THESEUS PHARMACEUTICALS INC / THRX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of THESEUS PHARMACEUTICALS INC (THRX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to THRX.


What is the valuation status for THRX stock?

ChartMill assigns a valuation rating of 0 / 10 to THESEUS PHARMACEUTICALS INC (THRX). This can be considered as Overvalued.


Can you provide the profitability details for THESEUS PHARMACEUTICALS INC?

THESEUS PHARMACEUTICALS INC (THRX) has a profitability rating of 1 / 10.


Can you provide the financial health for THRX stock?

The financial health rating of THESEUS PHARMACEUTICALS INC (THRX) is 9 / 10.